|
|
|
|
|
Related Brands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Categories
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC Medicines > Cough and Cold > Sore Throat Medications
|
Cepacol Maximum Strength Sore Throat Lozenges, Cherry - 18 Each |
Cepacol Maximum Strength Sore Throat Lozenges, Cherry temporary relieves sore throat pain, sore pain, canker sores. |
Usually Ships in 1 Business day. |
|
|
|
In Stock : |
Yes |
|
List Price : |
$4.99 |
|
Your Price : |
$3.99 |
|
|
|
|
Quantity : |
|
|
|
|
|
|
|
Part No : 391276 |
UPC : 300680209183 |
|
|
|
|
Description |
|
MANUFACTURER: COMBE INCORPORATED.
INDICATIONS:
Cepacol Maximum Strength Sore Throat Lozenges For
- Instant relief.
- Regular strength.
- #1 Brand in hospitals.
- Benzocaine/Menthol Oral Anesthetic Lozenges.
Cepacol maximum Strength Sore Throat Lozenges Temporarily relieves occasional:
- sore throat pain
- sore mouth
- minor mouth irritation
- and pain associated with canker sores
.
INGREDIENTS:
Active Ingredients:
Benzocaine 10 mg, Menthol 3. 6mg.
Inactive Ingredients:
Cetylpyridinium Chloride (Ceepryn), D&C Red No. 33, FD&C Red No. 40, Flavor, Glucose, Simethicone, Sucrose.
DIRECTIONS:
Adults and children 2 years or older dissolve 1 lozenge in the mouth every 2 hours as needed or as directed by a physician or dentist. Children under 2 years of age: consult a doctor.
WARNINGS:
Stop use and ask a doctor if: sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, swelling, nausea or vomiting; sore mouth symptoms do not improve in 7 days, or if irritation, pain or redness persists or worsens. Keep this and all drugs out of the reach of children. Do not use this product if you have a history of allergy to local anesthetics such as procaine; butacaine; benzocaine; or any other caine anesthetics. If pregnant or breast feeding, ask a health professional before use. Do not exceed recommended dosage. In case of overdose, get medical help or contact a Poison Control Center right away.
|
|
|
|
|
|
|